证券代码：688755 证券简称：汉邦科技 公告编号：2025-029 江苏汉邦科技股份有限公司 第二届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏汉邦科技股份有限公司（以下简称"公司"）第二届董事会第一次会议 于 2025 年 9 月 11 日以现场和通讯相结合的方式在公司会议室召开，会议通知于 2025 年 9 月 11 日在 2025 年第二次临时股东会召开完毕后即下发并送达第二届 董事会各董事，经全体董事一致同意，豁免本次会议通知时间的要求。本次会议 与会董事共同推举张大兵先生主持，会议应出席董事 9 人，实际出席董事 9 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、法规 和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，并对议案进行了投票表决，通过了以下决议： （一）审议通过了《关于选举公司第二届董事会董事长的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 经审议，董事会同意选举张大兵先生为公司第二届董 ...

资料显示，江苏汉邦科技股份有限公司位于江苏省淮安经济技术开发区新竹路10号,淮安经济技术开发 区集贤路1-9号，成立日期1998年10月28日，上市日期2025年5月16日，公司主营业务涉及为制药、生命 科学等领域提供专业的分离纯化装备、耗材、应用技术服务及相关的技术解决方案。主营业务收入构成 为：小分子药物分离纯化设备70.99%，大分子药物分离纯化设备22.94%，其他6.07%。 融资方面，汉邦科技当日融资买入475.91万元。当前融资余额9114.72万元，占流通市值的11.84%。 机构持仓方面，截止2025年6月30日，汉邦科技十大流通股东中，东方红医疗升级股票发起A （015052）位居第一大流通股东，持股48.37万股，为新进股东。 融券方面，汉邦科技9月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 责任编辑：小浪快报 9月9日，汉邦科技跌0.98%，成交额4461.88万元。两融数据显示，当日汉邦科技获融资买入额475.91万 元，融资偿还734.21万元，融资净买入-258.29万元。截至9月9日，汉邦科技融资 ...

Core Viewpoint - Hanbang Technology's stock experienced a 1.60% increase on September 8, with a trading volume of 73.06 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On September 8, Hanbang Technology had a financing buy-in amount of 6.97 million yuan, with a net financing purchase of 1.07 million yuan after 5.90 million yuan in financing repayments [1]. - The total financing and securities balance for Hanbang Technology reached 93.73 million yuan, accounting for 12.06% of its market capitalization [1]. - There were no securities sold or repaid on that day, indicating no short-selling activity [1]. Company Overview - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province [1]. - The company specializes in providing professional separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1]. - The revenue composition of Hanbang Technology includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1]. Financial Performance - As of June 30, 2025, Hanbang Technology reported a total revenue of 349 million yuan, reflecting a year-on-year growth of 5.99% [2]. - The net profit attributable to the parent company was 27.80 million yuan, showing a year-on-year decrease of 26.24% [2]. - The number of shareholders decreased by 48.43% to 9,372, while the average circulating shares per person increased by 93.92% to 1,764 shares [2]. Shareholding Structure - As of June 30, 2025, the largest circulating shareholder of Hanbang Technology is Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2].

证券代码：688755 证券简称：汉邦科技 公告编号：2025-026 江苏汉邦科技股份有限公司 关于收到《无效宣告请求审查决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 无效宣告请求审查结果：国家知识产权局经审查决定，思拓凡瑞典有限 公司拥有的发明专利"分离介质浆料罐"（专利号：200980125060.3）被宣告全 部无效。 公司所处的当事人地位：无效宣告请求人。 是否会对公司损益产生负面影响：本次无效宣告事项不会对公司的日常 生产经营产生负面影响，也不会对公司当期及未来的损益产生负面影响。 江苏汉邦科技股份有限公司（以下简称"公司"或"汉邦科技"）于近日收 到了中华人民共和国国家知识产权局（以下简称"国家知识产权局"）出具的《无 效宣告请求审查决定书》（第 588891 号）。国家知识产权局对无效宣告请求人 汉邦科技提出的思拓凡瑞典有限公司（英文名"Cytiva"）拥有的"分离介质浆 料罐"（专利号：200980125060.3）专利权之无效宣告请求进行了审查，审查结 论为宣告该专利权全部无效。现将有 ...

Group 1 - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss various proposals, including the election of the second board of directors [1][15][16] - The meeting will take place on September 11, 2025, at 14:30 in Huai'an, Jiangsu Province, and will combine on-site and online voting methods [6][13] - The company aims to ensure the legal rights of all shareholders and maintain order during the meeting, with specific registration and voting procedures outlined [2][4][5] Group 2 - Proposal 1 involves changing the company's business scope and amending the articles of association, specifically removing certain hazardous chemical operations [6][7] - Proposal 2 outlines the profit distribution plan for the first half of 2025, with a net profit of approximately 27.8 million yuan and a proposed cash dividend of 1.00 yuan per 10 shares, totaling 8.8 million yuan [13][14] - Proposals 3 and 4 focus on the election of non-independent and independent directors for the second board, with specific candidates nominated and their qualifications verified [15][16]

江苏汉邦科技股份有限公司 2025 年第二次临时股东会会议资料 证券代码：688755 证券简称：汉邦科技 江苏汉邦科技股份有限公司 2025 年第二次临时股东会会议资料 二〇二五年九月 | | | 江苏汉邦科技股份有限公司 2025 年第二次临时股东会会议资料 六、会议召开期间，股东准备在股东会发言的，应当事先在签到处登记，发 言前应当举手示意，经会议主持人许可方可发言。股东及代理人提问应围绕本次 会议议题，简明扼要，时间不超过 5 分钟。股东不得打断会议报告人的报告或其 他股东及股东代理人的发言,在股东会进行表决时，股东及股东代理人不再进行 发言。违反前述规定的，会议主持人可以拒绝或制止。 1 江苏汉邦科技股份有限公司 2025 年第二次临时股东会会议须知 为了维护全体股东的合法权益，确保公司股东会的正常秩序和议事效率，根 据《中华人民共和国公司法》(以下简称《公司法》)、《中华人民共和国证券法》 (以下简称《证券法》)、《上市公司股东会规则》以及《江苏汉邦科技股份有限 公司章程》(以下简称《公司章程》)等相关规定，特制订 2025 年第二次临时股 东会须知。 一、为保证本次会议的严肃性和正常秩序，切实维 ...

Group 1: Financial Performance - The company reported total revenue and other income of RMB 46.552 billion, a year-on-year increase of 16.28% [1] - Net profit attributable to shareholders was RMB 13.719 billion, reflecting a year-on-year increase of 29.79% [1] - Basic earnings per share were RMB 0.89, with a dividend of RMB 0.29 per share [1] Group 2: Domestic Business Performance - The company maintained a leading position in domestic equity financing, completing 36 A-share underwriting projects with a total underwriting scale of RMB 148.528 billion, capturing a market share of 19.19% [1] - In the bond underwriting sector, the company underwrote 2,821 bonds with a total scale of RMB 1,038.725 billion, a year-on-year increase of 11.61%, representing 6.65% of the total market and 14.15% of the securities firms' total scale [2] - The company ranked first in underwriting financial bonds, association products, and asset-backed securities [2] Group 3: Support for Technology and Innovation - The company supported technology-driven enterprises in issuing and listing, achieving an equity underwriting scale of RMB 26.1 billion in the Sci-Tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange, ranking first in the market [2] - The company completed six major asset restructuring transactions with a total scale of RMB 37.005 billion, holding a market share of 16.09% [2] Group 4: International Development - The company completed 30 overseas equity projects with an underwriting scale of USD 2.989 billion, including significant IPOs in the Hong Kong market [3] - The company underwrote 160 offshore bond projects with a total scale of USD 2.4 billion, ranking second in the market [3] - The company facilitated 29 global M&A projects involving Chinese enterprises, with a total transaction scale of USD 20.962 billion [3]

Market Overview - The medical device sector experienced a decline of 1.98% on August 27, with Hanbang Technology leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Top Gainers in Medical Device Sector - Aomei Medical (002950) saw a closing price of 10.74, with a significant increase of 10.04% and a trading volume of 436,600 shares, totaling a transaction value of 467 million yuan [1] - Jimin Health (603222) closed at 10.04, up 9.97%, with a trading volume of 1,165,700 shares, amounting to 1.118 billion yuan [1] - Meihai Medical (301363) closed at 25.58, increasing by 4.45% with a trading volume of 463,000 shares, totaling 1.22 billion yuan [1] Top Decliners in Medical Device Sector - Hanbang Technology (688755) closed at 47.70, down 11.91%, with a trading volume of 62,100 shares, resulting in a transaction value of 305 million yuan [2] - Rejing Bio (688068) closed at 211.99, decreasing by 10.47%, with a trading volume of 44,900 shares [2] - Wuzhou Medical (301234) closed at 42.83, down 8.13%, with a trading volume of 54,400 shares, totaling 239 million yuan [2] Capital Flow Analysis - The medical device sector saw a net outflow of 2.272 billion yuan from institutional investors, while retail investors experienced a net inflow of 1.684 billion yuan [2] - Jimin Health (603222) had a net inflow of 105 million yuan from institutional investors, but a net outflow of 30.37 million yuan from retail investors [3] - Aomei Medical (002950) recorded a net inflow of 83.90 million yuan from institutional investors, with a net outflow of 43.40 million yuan from retail investors [3]

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. reported a revenue of 349 million yuan and a net profit of 27.8 million yuan for the first half of 2025, alongside a cash dividend plan of 8.8 million yuan to shareholders [2] Group 1: Financial Performance - The company achieved a revenue of 349 million yuan and a net profit of 27.8 million yuan during the reporting period [2] - The small molecule business generated a revenue of 248 million yuan, reflecting a year-on-year growth of 17.44% [2] - The compound annual growth rate (CAGR) of the company's revenue from 2022 to 2024 is 19.75% [2] Group 2: R&D and Technological Advancements - The company has overcome challenges in chromatography linear scaling technology, enabling product scaling from grams to kilograms [3] - R&D expenses for the first half of the year amounted to 20.99 million yuan, with a CAGR of 20.14% in R&D investment over the past three years [3] - Ongoing projects include the development of high-efficiency peptide synthesis and purification equipment, utilizing advanced industry technologies [3] Group 3: Market Outlook and Strategic Focus - The global chromatography equipment market is expanding, particularly in China, driven by the rapid development of downstream industries [3] - The company plans to continue focusing on its core chromatography product business, enhancing product performance based on market demand [3] - The goal is to become a leading enterprise in the R&D, production, and industrialization of chromatography separation and purification equipment in China [3]

Group 1 - The core point of the news is the significant performance of Aojie Technology-U on the STAR Market, with its stock price reaching 122.40 yuan and a trading volume of 1.976 billion yuan, indicating strong market interest [2] - As of the report, 388 stocks on the STAR Market were rising, with 23 stocks increasing by over 10%, including Aojie Technology-U, Kaipu Cloud, Nanjing New Pharmaceutical, and Lexin Technology [2] - Conversely, 196 stocks were declining, with notable drops from Jingpin Special Equipment, Rejing Biology, and Hanbang Technology, which fell by 10.36%, 9.98%, and 8.72% respectively [2] Group 2 - In terms of capital flow, Aojie Technology-U experienced a net outflow of 112 million yuan in the previous trading day, with a total net outflow of 79.3369 million yuan over the last five days [3] - The latest margin trading data shows that as of August 26, the total margin balance for Aojie Technology-U was 722 million yuan, with a financing balance of 710 million yuan, reflecting an increase of 8.0892 million yuan or 1.15% from the previous trading day [3] - The total margin balance increased by 259 million yuan over the last ten days, representing a growth of 56.02%, with financing balance growth of 57.10% and a 10.65% increase in the margin balance [3]